Clinical Update provided on Ph 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety and Efficacy Data Observed in a Patient with MDS/AML
“The evolution of this trial to MDS and MF is an important milestone as we continue to dose escalate, both in terms of volume and frequency. We are looking forward to sharing additional details in our call this afternoon, and to communicating with all stakeholders – including regulatory authorities – toward the continuing of its development. We also remain grateful to our trial patients for their participation as well as the loyal and long-time shareholders who continue to ensure that the Company is able to conduct this work. We remain focused on the careful and deliberate conduct of the dose-escalation phase and the systematic collection of safety data as the trial proceeds and we seek to expand its initial focus,” said CERo CEO Chris Ehrlich.
Share:
More News
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit
“We are excited to work with Merck to advance this promising investigational combination in RAS-driven cancers,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “RAS mutations activate the RAS/MAPK pathway and promote an immunosuppressive environment. Non-clinical data suggest that targeting the pathway with ERAS-0015 may complement PD-1 blockade
“Dosing the first patient in the ASPENOVA Phase 3 clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “With DENALI Part 2 progressing toward a year-end readout that may support accelerated approval and
“The depth, durability, and consistency of responses observed across both the total population and BTKi-treated subsets underscore iopofosine’s potential as a meaningful new treatment option in WM and differentiate it from currently available therapies,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “With the completion of at least 12-month